Literature DB >> 23252362

The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension.

Marco daCosta DiBonaventura1, Laquesha M Andrews, Anthony M Yadao, Kristijan H Kahler.   

Abstract

Although gout has been found to be associated with health-related quality of life (HRQoL), few studies have examined the burden of gout in the presence of concomitant cardiometabolic conditions. The present study evaluated the effect of gout on HRQoL and work productivity among patients with hypertension. Data from the 2010 National Health and Wellness Survey were obtained for respondents ≥18 years of age who had self-reported, physician-diagnosed hypertension or blood pressure levels ≥140/90 mmHg (≥130/80 mmHg for those with physician-diagnosed diabetes or chronic kidney disease). Bivariate analysis was used to evaluate differences between patients with and without self-reported comorbid gout. Generalized linear models were used to evaluate differences in productivity (using the Work Productivity and Activity Impairment scale) and HRQoL (using the physical component summary [PCS], mental component summary and health utilities from the SF-12v2 health survey). As uric acid levels may influence other organ systems, core modeling did not include comorbidities other than osteoarthritis and depression as covariates. Sensitivity analyses were controlled for the Charlson comorbidity index. A total of 22,686 patients with self-reported hypertension met study eligibility requirements. Of these, 4.51% reported having gout. These patients were older, more likely to be male and have insurance through Veteran Affairs (all p-values < 0.05). Patients with comorbid gout reported lower levels of mental component summary scores (47.25 vs 48.93), PCS scores (39.06 vs 43.78) and health utilities (0.68 vs 0.73; all p-values < 0.05). For both PCS and health utilities, differences between groups exceeded clinically meaningful cutoffs. Sensitivity analyses conducted on PCS and health utilities uncovered slightly smaller, but statistically significant and clinically meaningful, effects (p-values < 0.05). The effect of gout on overall work impairment (23.33 vs 17.40% with and without comorbid gout, respectively) remained after controlling for the Charlson comorbidity index. Significantly greater impairment in daily activities (38.96 vs 28.32%; p < 0.05) was also observed among patients with comorbid gout. Results demonstrate that gout has significant and clinically meaningful impact on work productivity, physical HRQoL and utilities independent of other health conditions.

Entities:  

Mesh:

Year:  2012        PMID: 23252362     DOI: 10.1586/erp.12.60

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

Review 1.  Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.

Authors:  Paul S J Miller; Harry Hill; Fredrik L Andersson
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

2.  Predictors of activity limitation in people with gout: a prospective study.

Authors:  Sarah Stewart; Keith Rome; Alastair Eason; Meaghan E House; Anne Horne; Anthony J Doyle; Julie Knight; William J Taylor; Nicola Dalbeth
Journal:  Clin Rheumatol       Date:  2018-04-21       Impact factor: 2.980

Review 3.  A Systematic Review of the Economic and Humanistic Burden of Gout.

Authors:  Gemma E Shields; Stephen M Beard
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

4.  Pilot study of a multidisciplinary gout patient education and monitoring program.

Authors:  Theodore R Fields; Adam Rifaat; Arthur M F Yee; Dalit Ashany; Katherine Kim; Matthew Tobin; Nicole Oliva; Kara Fields; Monica Richey; Shanthini Kasturi; Adena Batterman
Journal:  Semin Arthritis Rheum       Date:  2016-10-24       Impact factor: 5.532

Review 5.  How Can We Improve Disease Education in People with Gout?

Authors:  Theodore R Fields; Adena Batterman
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

6.  Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.

Authors:  Roy Fleischmann; Peter Winkle; Jesse Hall; Shakti Valdez; Sha Liu; Xiaohong Yan; Liz Hicks; Caroline Lee; Jeffrey N Miner; Michael Gillen; Martha Hernandez-Illas
Journal:  RMD Open       Date:  2018-04-09

7.  Validation of Global Self-Rated Health and Happiness Measures Among Older People in the Yilan Study, Taiwan.

Authors:  Yen-Huai Lin; Hsi-Chung Chen; Nai-Wei Hsu; Pesus Chou
Journal:  Front Public Health       Date:  2020-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.